Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Inhibrx Biosciences, Inc
Hookipa Biotech GmbH
Hookipa Biotech GmbH
UNICANCER
Seagen Inc.
Leiden University Medical Center
University of Alabama at Birmingham
MultiVir, Inc.